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 Case fatality rates in adults with severe falci-
parum malaria (SM) remain high despite the use 
of rapidly parasiticidal antimalarial chemother-
apy ( 1 ). Adjunctive therapies (in addition to anti-
malarial treatment) have been used in an attempt 
to reduce mortality, but none have proved eff ec-
tive to date ( 2 ). Targeted interventions with novel 
adjunctive agents require a better understanding of 
the pathophysiologic processes that occur in SM. 
 The vascular endothelium plays a central role 
in the pathogenesis of SM. Parasitized red cells 
adhere to constitutive and cytokine-inducible 
receptors on the microvascular endothelium, 
resulting in sequestration and vascular obstruction, 
impaired perfusion, and tissue dysoxia in critical 
organs ( 3 – 6 ). This cytoadherence is associated 
with in vitro and histopathological evidence of 
endothelial infl ammation and damage ( 4, 5, 7, 8 ). 
However, there have been no studies examining 
endothelial function in SM in vivo. 
 Our previous studies in African children 
with SM demonstrated impaired production of 
NO ( 9 ), impaired mononuclear cell NO synthase 
type 2 (NOS2) expression ( 9 ), and low plasma 
concentrations of  l -arginine ( 10 ), the substrate for 
NO synthesis from NOS. In an animal model of 
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 Severe falciparum malaria (SM) is associated with tissue ischemia related to cytoadherence 
of parasitized erythrocytes to microvascular endothelium and reduced levels of NO and its 
precursor,  l  -arginine. Endothelial function has not been characterized in SM but can be 
improved by  l  -arginine in cardiovascular disease. In an observational study in Indonesia, we 
measured endothelial function using reactive hyperemia – peripheral arterial tonometry 
(RH-PAT) in 51 adults with SM, 48 patients with moderately severe falciparum malaria (MSM), 
and 48 controls. The mean RH-PAT index was lower in SM (1.41; 95% confi dence interval 
[CI]  1.33 – 1.47) than in MSM (1.82; 95% CI  1.7 – 2.02) and controls (1.93; 95% CI  
1.8 – 2.06; P  < 0.0001). Endothelial dysfunction was associated with elevated blood lactate 
and measures of hemolysis. Exhaled NO was also lower in SM relative to MSM and controls. 
In an ascending dose study of intravenous  l  -arginine in 30 more patients with MSM, 
 l  -arginine increased the RH-PAT index by 19% (95% CI  6 – 34; P  0.006) and exhaled NO 
by 55% (95% CI  32 – 73; P  < 0.0001) without important side effects. Hypoargininemia 
and hemolysis likely reduce NO bioavailability. Endothelial dysfunction in malaria is nearly 
universal in severe disease, is reversible with  l  -arginine, and likely contributes to its patho-
genesis. Clinical trials in SM of adjunctive agents to improve endothelial NO bioavailability, 
including  l  -arginine, are warranted. 
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 l -arginine infusion in acute malaria would improve endo-
thelial function. In stage 2, we undertook a single ascending 
dose study of  l -arginine infusion in hospitalized patients with 
moderately severe falciparum malaria (MSM) to demonstrate 
safety and  “ proof of concept ” of  l -arginine infusion as a po-
tential adjunctive therapy targeting the endothelium in malaria. 
 RESULTS 
 Stage 1 
 Subjects.  Out of the 158 patients enrolled, 5 were excluded 
from the SM group because of an alternative diagnoses and 6 
were excluded from the control group because of asymptom-
atic parasitemia ( Fig. 1 ). Baseline characteristics of the remain-
ing 147 patients are shown in  Table I . Among the 51 patients 
with SM, 28 (55%) had coma, 17 (33%) had acute renal failure, 
23 (45%) had hyperbilirubinemia with either renal impairment 
or parasitemia (  100,000 parasitemia/  l), and 30 (59%) had 
more than one criterion for severe disease ( 22 ). In total, 35 
(69%) patients received artesunate and 16 (31%) received qui-
nine. All of the 48 patients with MSM were treated with qui-
nine except for one, who received artesunate. There were 
seven (14%) deaths among SM patients and none in the MSM 
group. Measurement of exhaled NO was possible in 88% (42 
out of 48) of MSM patients and 48% (11 out of 23) of SM pa-
tients without coma. Reactive hyperemia – peripheral arterial 
tonometry (RH-PAT) could be assessed in 99% (145 out 
of 147), with restlessness precluding reliable measurement in 
2 patients with SM. 
 Endothelial function. The mean RH-PAT index was 1.41 
(95% confi dence interval [CI]  1.33 – 1.47) in patients with 
SM ( n  49), which was signifi cantly lower than in patients 
with MSM (1.82; 95% CI  1.7 – 2.02;  n  48) or healthy 
controls (HC; 1.93; 95% CI  1.8 – 2.06;  n  48; P   0.0001; 
 Fig. 2 A ). There was no signifi cant diff erence between the 
HC and MSM groups (P  0.49). Overall, the proportion of 
cerebral malaria, reduced NO availability is associated with 
increased mortality and NO replacement improves survival ( 11 ). 
In vitro, NO reduces the expression of cytokine-inducible 
adhesion molecules on endothelial cells ( 12 ) and decreases 
cytoadherence of parasitized erythrocytes to the microvascular 
endothelium ( 13 ). Impaired in vivo endothelial NO produc-
tion in malaria is likely to exacerbate these processes. 
 An additional mechanism of reduced NO availability has 
recently been described in disease states with intravascular 
hemolysis ( 14 ). Erythrocyte rupture results in increased cell-free 
hemoglobin and plasma arginase ( 15, 16 ), leading to increased 
NO consumption and plasma  l -arginine catabolism, respec-
tively, and an overall reduction in NO bioavailability ( 14 ). In 
sickle cell disease (SCD), these mechanisms are thought to 
contribute to endothelial dysfunction and mortality ( 16 – 18 ). 
Because hemolysis is found in malaria, these processes may also 
contribute to NO defi ciency, endothelial dysfunction, and 
pathogenesis in SM; however, human studies relative to this 
 issue are lacking. 
 Endothelial function is characterized by the ability of ves-
sels to dilate in response to increased shear stress or chemical 
agonists and is inversely related to endothelial activation ( 19 ). 
Impaired endothelial function is found in chronic diseases 
such as hypercholesterolemia ( 19 ) and lysinuric protein intol-
erance (an inherited defi ciency of  l -arginine uptake) ( 20 ), both 
of which improve with  l -arginine therapy ( 20, 21 ). It is un-
known whether restoration of plasma  l -arginine concentrations 
can improve endothelial function in acute infections such 
as malaria. 
 Our fi rst hypothesis was that endothelial function, exhaled 
NO, and plasma  l -arginine concentrations would be reduced 
in adults with falciparum malaria in proportion to disease 
severity, and that measures of hemolysis would be associated 
with endothelial dysfunction. In stage 1 of this study, we 
therefore compared each of these parameters among pa-
tients with and without SM. Our second hypothesis was that 
 Figure 1.  Study profi le of patients recruited in stages 1 and 2 of the study. Stage 1 was an observational study to compare endothelial function 
among individuals with SM, MSM, and HC. Stage 2 was intervention study to measure the effect of  L -arginine or saline infusion on RH-PAT index and 
exhaled NO in MSM. 
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[95% CI  795 – 1,080] vs. 518 pg/ml [95% CI  470 – 566]; 
P   0.0001;  Table II ), and E-selectin (152 pg/ml [95% CI  
113 – 192] vs. 94 pg/ml [95% CI  83 – 106]; P   0.0001; 
 Table II ). Plasma histidine-rich protein 2 (HRP2), a measure 
of total parasite biomass, was also signifi cantly higher in pa-
tients with severe disease (P   0.0001;  Table II ). 
 Baseline measures of hemolysis. Plasma haptoglobin con-
centrations were below the lower limit of detection (10 mg/dl) 
in 92% (45 out of 49) of patients with SM compared with 
45% (22 out of 48) of those with MSM (relative risk  2; 95% 
CI  1.46 – 2.76; P   0.0001;  Table II ). Plasma lactate dehy-
drogenase (LDH) concentrations increased with disease sever-
ity (P   0.0001;  Table II ); in pairwise comparisons, the mean 
plasma LDH concentration was signifi cantly higher in patients 
with SM (1,667 IU/liter; 95% CI  1,439 – 1,882]) than in 
MSM patients (660 IU/liter; 95% CI  563 – 757; P   0.001) 
or HC (447 IU/liter; 95% CI  373 – 522; P   0.001). In pa-
tients with SM, mean LDH concentrations were signifi cantly 
higher in those with a fatal outcome (2,394 IU/liter; 95% 
CI  1,834 – 3,054) than in survivors (1,526 IU/liter; 95% CI  
1,306 – 1,747; P  0.009). Plasma LDH was also positively 
subjects with impaired endothelial function (RH-PAT   
1.67) ( 23 ) was signifi cantly higher in SM patients (46 out of 
49; 94%) compared with that in patients with MSM (17 out of 
48; 35%) or HC (14 out of 48; 29%; P   0.0001;  Fig. 2 A ). 
In patients with SM, there was no signifi cant diff erence in the 
RH-PAT index among patients according to severity criteria 
(P  0.32) ( 22 ) or mortality (P  0.66). 
 Baseline concentrations of plasma  L -arginine and bio-
markers of disease severity. Plasma  l -arginine concentrations 
were lower in both the MSM (42   mol/liter; 95% CI  37 – 45) 
and SM groups (49   mol/liter; 95% CI  43 – 55) relative to 
controls (77   mol/liter; 95% CI  68 – 85; P   0.0001; 
 Table II and  Fig. 2 B ). In patients with SM, there was no signi-
fi cant diff erence in mean  l -arginine concentrations among 
diff erent severity criteria (P  0.15). There was no signifi cant 
diff erence in the plasma  l -arginine/ornithine ratios among 
groups (P  0.14;  Table II ). Compared with patients with 
MSM, patients with SM had higher mean concentrations of 
lactate (2.89 mmol/liter [95% CI  2.34 – 3.44] vs. 1.36 
mmol/liter [95% CI  1.17 – 1.55]; P   0.0001;  Table II ), 
soluble intercellular adhesion molecule 1 (ICAM-1; 937 pg/ml 
 Table I.  Baseline characteristics of stage 1 patients according to clinical status 
HC MSM SM
Number 48 48 51
Age (y):  
 mean (range)
27 (18 – 42) 28 (18 – 56) 29 (18 – 56)
Males:  
 no. (%)
31 (65) 32 (67) 37 (72)
Weight (kg):  
 mean (range)
59 (42 – 73) 58 (43 – 77) 57 (45 – 85)
Ethnicity:  
 no. (%) Papuan highlander*
42 (87) 37 (77) 27 (53)
Current smoker:  
 no. (%)
23 (48) 19 (40) 22 (43)
Exsmoker:  
 no. (%)*
3 (6) 7 (14) 8 (15)
Days of fever before presentation:  
 median (IQR) ‡ 
NA 2 (1-5) 4 (1-7)
Systolic blood pressure (mmHg):  
 mean (range) ‡ 
130 (96 – 136) 114 (88 – 152) 106 (60 – 154)
Hypertensive on enrollment (%) 0 2 2
Pulse rate (beats/min):  
 mean (range) ‡ 
68 (44 – 104) 86 (56 – 118) 97 (61 – 138)
Respiratory rate (breaths/min):  
 mean (range) ‡ 
20 (18 – 26) 25 (14 – 42) 30 (16 – 60)
Temperature ( ° C):  
 mean (range) ‡ 
35.6 (35 – 36.7) 36.5 (34.1 – 39.8) 37.1 (34.8 – 40.3)
Coma:  
 no. (%)*
0 0 28 (55)
Time (h) from start of antimalarial  
 therapy to physiological testing:  
 mean (95% CI) ‡ 
NA 4.5 (3 – 6) 8 (6 – 10)
*, P   0.01, calculated from a   2 test comparing SM, MSM (stage 1), and HC.  ‡ , P   0.01, calculated from ANOVA comparing SM, MSM (stage 1), and HC; or where no data in 
HC, calculated from a two-sided  t test comparing SM and MSM (stage 1). IQR, interquartile range; NA, not applicable.
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correlated with both plasma arginase activity (r  0.4; P   
0.001) and plasma ICAM-1 (r  0.75; P   0.001) and 
E-selectin (r  0.47; P   0.001), and these correlates remained 
after stratifying for disease severity. Plasma arginase activity 
increased with disease severity (P  0.0002;  Table II ) and was 
weakly associated with plasma ICAM-1 (r  0.27; P  0.01) 
and E-selectin (r  0.25; P  0.02) but not with plasma 
 l -arginine concentrations. 
 Relationship between endothelial function and bio-
markers of disease severity and hemolysis. Among all 
malaria patients ( n  99), the RH-PAT index was negatively 
correlated with plasma HRP2 (parasite biomass; r   − 0.38; 
P   0.0001), lactate concentrations (r   − 0.34; P  0.001), 
plasma LDH concentrations (r   − 0.41; P   0.001), plasma 
arginase activity (r   − 0.3; P  0.004), and plasma-soluble 
ICAM-1 concentrations (r   − 0.45; P   0.0001), but not ex-
haled NO, hemoglobin, bilirubin, E-selectin,  l -arginine, or the 
 l -arginine/ornithine ratio. After stratifying by disease severity, 
blood lactate and plasma LDH concentrations remained cor-
related with the RH-PAT index. In the 26 patients with MSM 
who had hapto globin concentrations in the measurable range, 
there was a signi fi cant association between plasma haptoglobin 
concentrations and the RH-PAT index (r  0.62; P  0.003). 
 Exhaled NO. Median exhaled NO was lower in the SM 
group (10.5 parts per billion [ppb]; range  4.4 – 27.5;  n  11) 
compared with the MSM (16.5 ppb; range  6.2 – 77.1;  n  42) 
and HC (16.5 ppb; range  4.9 – 67.1;  n  48) groups (P  
0.049;  Fig. 2 C ). After stratifying by disease category, there was 
no association between exhaled NO and plasma  l -arginine 
concentration or any measure of hemolysis. 
 Stage 2 
 Subjects. A total of 30 patients received  l -arginine infusion 
intravenously at doses of 3 ( n  10), 6 ( n  10), and 12 g ( n  10). 
Their baseline clinical and physiological characteristics did not 
diff er signifi cantly from the stage 1 patients with MSM who 
received an identical volume of saline ( Table III ). 
 Eff ect of  L -arginine infusion on plasma  L -arginine and 
RH-PAT. Overall, plasma  l -arginine concentrations increased 
in all subjects receiving  l -arginine. The mean  l -arginine con-
centration increased from 37   mol/liter (95% CI  33 – 43) 
to 853   mol/liter (95% CI  628 – 1,078; P   0.0001), with 
maximum values observed at the end of the 30-min infusion. 
The increases in peak  l -arginine concentrations were dose 
related, with the mean after 3, 6, and 12 g being 288 (95% CI  
172 – 405), 809 (95% CI  592 – 1,027), and 1,310   mol/liter 
(95% CI  911 – 1,709), respectively. There was no signifi cant 
change in plasma  l -arginine after saline infusion (P  0.89). 
 After  l -arginine infusion at any dose ( n  30), the overall 
mean RH-PAT index rose from 1.76 (95% CI  1.62 – 1.9) to 
2.05 (95% CI  1.84 – 2.26), a 19% (95% CI  6 – 34) increase 
(P  0.006;  Fig. 3 A ). The proportion of patients with an ab-
normal RH-PAT (  1.67) decreased from 47% (14 out of 30) to 
 Figure 2.  RH-PAT index, plasma  L -arginine concentrations, and 
exhaled NO in each study group at enrollment. (A) Comparison of 
RH-PAT index at enrollment among disease categories (P   0.0001 by 
ANOVA). Dots and error bars indicate means and 95% CIs. Horizontal line 
indicates an RH-PAT index of 1.67; values below this represent impaired 
endothelial function (reference  23 ). (B) Comparison of plasma  L -arginine 
concentrations among disease categories (P   0.0001 by ANOVA). Dots 
and bars indicate means and 95% CIs. (C) Comparison of exhaled NO 
concentrations at enrollment among disease categories (P  0.049 by the 
Kruskal-Wallis test). Central line and box indicate the median and inter-
quartile range. Whiskers indicate range. 
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no signifi cant diff erence compared with those who received 
saline ( − 5% mean relative change; 95% CI  from  − 20 to 9; 
P  0.2). In these patients, there was also no signifi cant diff er-
ence in the proportion in whom the RH-PAT index fell below 
1.67 after  l -arginine (12%) compared with saline (9%; P  0.7). 
 Eff ect of  L -arginine infusion on exhaled NO. Paired mea-
surements were available for 27 patients after  l -arginine infu-
sion at any dose, with 3 patients unable to perform the procedure. 
The mean exhaled NO increased from 21.2 ppb (95% CI  
15.9 – 26.4) to 31.8 ppb (95% CI  23.9 – 9.7), an increase of 
55% (95% CI  32 – 73; P   0.0001;  Fig. 3 C ). There was no 
signifi cant change in exhaled NO after saline infusion (P  0.1; 
 Fig. 3 C ). The mean relative increase in exhaled NO after 
 l -arginine infusion was 37% higher (95% CI  15 – 59) when 
compared with saline administration (P  0.002). 
 Safety.  l -arginine infusion was well tolerated. Two patients ex-
perienced mild pain at the infusion site, but there were no other 
adverse eff ects or clinically important changes in vital signs. 
23% (7 out of 30; P  0.01). In the control group, there was 
no overall change in the RH-PAT index after infusion of 
saline (P  0.76;  Fig. 3 A ). The diff erence in mean relative 
increase in the RH-PAT index after  l -arginine infusion 
compared with that after saline administration was 16% (95% 
CI  1 – 32; P  0.04). 
 In the a priori – selected subgroup of 14 subjects with base-
line endothelial dysfunction (RH-PAT index   1.67) who re-
ceived  l -arginine infusion, the mean RH-PAT index rose from 
1.46 (95% CI  1.37 – 1.55) to 1.99 (95% CI  1.61 – 2.38), a 
relative increase of 38% (95% CI  11 – 65; P  0.004). Among 
patients with baseline impairment of endothelial function, there 
was a signifi cant dose – response with  l -arginine infusion, with a 
mean increase in the RH-PAT index of 12% (95% CI  from 
 − 1 to 25) in those receiving 3 g ( n  4), 24% (95% CI  from 
 − 5 to 54) receiving 6 g ( n  6), and 78% (95% CI  from  − 16 
to 173) receiving 12 g ( n  4; P  0.03;  Fig. 3 B ). 
 In patients with an RH-PAT index   1.67, there was no 
signifi cant change in RH-PAT before and after  l -arginine (5% 
mean relative change; 95% CI  from  − 7 to 17; P  0.5), and 
 Table II.  Laboratory and physiological results of stage 1 patients according to clinical status 
HC MSM SM
Number 48 48 51
White blood cell count (  10 3   l   1 ):  
 mean (95% CI) ‡ 
ND 5.9 (2.6 – 10.8) 9.4 (3.2 – 17.3)
Hemoglobin (g/liter):  
 mean (range) ‡ 
ND 128 (7.1 – 16.7) 108 (6 – 16.3)
Plasma  L -arginine (  mol/liter):  
 mean (95% CI) ‡ 
77 (68 – 85) 42 (37 – 45) 49 (43 – 55)
Plasma ornithine (  mol/liter):  
 mean (95% CI) ‡ 
71 (62 – 80) 50 (39 – 60) 60 (43 – 77)
 L -arginine/ornithine ratio:  
 mean (95% CI)
1.15 (1 – 1.29) 0.99 (0.84 – 1.14) 1.03 (0.89 – 1.17)
Plasma arginase activity (  mol/ml/h):  
 median (IQR)**
0.14 (0.06 – 0.19) 0.18 (0.12 – 0.24) 0.24 (0.17 – 0.31)
Lactate concentration (mmol/liter):  
 mean (95% CI) ‡ 
NA 1.36 (1.1 – 1.5) 2.89 (2.3 – 3.4)
Haptoglobin undetectable (  10mg/dl):  
 no. (%) ‡ 
ND 22/48 (45) 45/49 (92)
Parasite density (  l   1 )  
 geometric mean (range) ‡ 
0 13,297 (850 – 127,350) 35,067 (125 – 725,340)
HRP2 concentration (log e  ng/ml):  
 mean (range) ‡ 
NA 5.78 (1.7 – 8.79) 7.53 (1 – 10.98)
LDH (IU/liter):  
 mean (95% CI) ‡ 
447 (373 – 522) 660 (563 – 757) 1667 (1,439 – 1,882)
Soluble ICAM-1 (pg/ml):  
 mean (95% CI) ‡ 
NA 518 (470 – 566) 937 (795 – 1,080)
Soluble E-selectin (pg/ml):  
 mean (95% CI) ‡ 
NA 94 (83 – 106) 152 (113 – 192)
RH-PAT index:  
 mean (95% CI) ‡ 
1.93 (1.8 – 2.06) 1.82 (1.7 – 2.02) 1.41 (1.33 – 1.47)
Exhaled NO (ppb):  
 median (IQR)**
16.5 (11.6 – 26.6) 16.5 (10.9 – 25.2) 10.5 (7.5 – 15)
 ‡ , P   0.01, calculated from ANOVA or a   2 test comparing SM, MSM (stage 1), and HC; or where no data in HC, calculated from a two-sided  t test comparing SM and MSM 
(stage 1). **, P   0.05, calculated from a Kruskal-Wallis test comparing SM, MSM (stage 1), and HC. IQR, interquartile range; NA, not applicable; ND, not done.
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cant changes in concentrations of blood glucose or electrolytes 
(potassium, phosphate, bicarbonate, chloride, and pH). 
 DISCUSSION 
 Autopsy studies in fatal cases of malaria have described cyto-
adherence of parasitized red cells to endothelium, endothelial 
inflammation, and endothelial damage ( 5 ). Our study has 
shown impairment of endothelium-dependent vasodilatation 
Mean changes in systolic blood pressure before and after infu-
sion of 3 g ( − 0.4 mmHg; 95% CI  from  − 5 to 6), 6 g (2 mmHg; 
95% CI  from  − 7 to 11), and 12 g ( − 3 mmHg; 95% CI  
from  − 13 to 8) were not clinically signifi cant. Mean changes in 
pulse rate before and after infusion of 3 g ( − 1 beat/min; 95% 
CI  from  − 9 to 7), 6 g ( − 4 beats/min; 95% CI  from  − 6 to 
14), and 12 g (1 beat/min; 95% CI  from  − 19 to 21) were also 
not clinically signifi cant. There were also no clinically signifi -
 Table III.  Baseline characteristics of the stage 2 patients with MSM given either saline or  L -arginine 
Saline infusion group a  L -arginine infusion group
Number 48 30
Age (y):  
 mean (range)
28 (18 – 56) 28 (18 – 54)
Males:  
 no. (%)
32 (67) 20 (67)
Weight (kg):  
 mean (range)
58 (43 – 77) 58 (42 – 70)
Ethnicity: no.  
 (%) Papuan highlander
37 (77) 23 (77)
Current smoker:  
 no. (%)
19 (40) 11 (37)
Exsmoker:  
 no. (%)
7 (14) 4 (13)
Days of fever before presentation:  
 median (IQR)
2 (1 – 5) 2 (1 – 4)
Systolic blood pressure (mmHg):  
 mean (range)
114 (88 – 152) 109 (90 – 138)
Hypertensive on enrollment (%) 2 0
Pulse rate (beats/min):  
 mean (range)
86 (56 – 118) 80 (54 – 116)
Respiratory rate (breaths/min):  
 mean (range)
25 (14 – 42) 24 (18 – 32)
Temperature ( ° C):  
 mean (range)
36.5 (34.1 – 39.8) 37 (34.8 – 40.2)
White blood cell count (  10 3   l   1 ):  
 mean (range)
5.9 (2.6 – 10.8) 6.2 (2.3 – 11.7)
Hemoglobin (g/liter):  
 mean (95% CI)
128 (7.1 – 16.7) 123 (7.5 – 17)
Plasma  L -arginine (  mol/liter):  
 mean (95% CI)
42 (37 – 45) 37 (33 – 43)
Lactate concentration (mmol/liter):  
 mean (95% CI)
1.29 (1.1 – 1.5) 1.5 (1.2 – 1.8)
RH-PAT index:  
 mean (95% CI)
1.82 (1.7 – 2.02) 1.76 (1.62 – 1.9)
Exhaled NO (ppb):  
 mean (range)
20.5 (6.2 – 77.1) 21.2 (4.2 – 51.3)
Parasite density (  l  − 1 ):  
 geometric mean (range)
16,297 (850 – 227,350) 17,221 (890 – 281,864)
HRP2 concentration (log e  ng/ml):  
 mean (range)
5.78 (1.7 – 8.79) 5.76 (1.34 – 8.79)
Time (h) from start of antimalarial  
 therapy to physiological testing:  
 mean (95% CI)
4.5 (3 – 6) 6 (4.5 – 7.5)
There was no signifi cant difference (P   0.05) between groups for any of the variables.
 a The patients with MSM given saline were those enrolled in stage 1 of the study.
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SM and its signifi cant improvement after infusion of  l- arginine 
(but not saline) in patients with MSM demonstrate that the 
endothelium can be targeted for adjunctive treatment in falci-
parum malaria. 
 Our measure of endothelial function, RH-PAT, is at least 
50% dependent on endothelial NO production ( 24 ). The en-
dothelial dysfunction present in SM and its reversibility with 
 l- arginine in MSM suggests a defi ciency of NO availability 
in a cell type central to the pathophysiology of SM. Further-
more, the association between endothelial dysfunction and 
both soluble ICAM-1 and total parasite biomass supports the 
hypothesis that impaired NO production in SM contributes 
to enhanced expression of endothelial adhesion molecules 
and the exacerbation of cytoadherence and sequestration. 
In myocarditis, coronary vessel endothelial ICAM-1 expres-
sion is also inversely associated with NO-dependent endo-
thelial function ( 25 ). 
 Plasma  l- arginine concentrations, exhaled NO levels, and 
endothelial function were all signifi cantly reduced in Indone-
sian adults with SM, which was consistent with the reduction 
in systemic NO production and hypoargininemia found in 
our previous studies in African children with cerebral malaria 
( 9, 10 ). Although data in severe malarial anemia are lacking, 
our fi ndings suggest that hypoargininemia and low NO bio-
availability are characteristic of SM across diff erent age groups, 
transmission intensities, ethnic groups, and disease manifesta-
tions. The increase in exhaled NO and endothelial function 
after  l- arginine infusion in MSM supports our earlier hypoth-
esis that hypoargininemia contributes to impaired NO bio-
availability in SM ( 10 ). 
 The rapid reversibility of endothelial dysfunction with 
 l- arginine infusion in MSM suggests that in addition to the 
physical obstruction found in small vessels, there may also be 
a functional defect in perfusion resulting from an impaired 
ability of small vessels to appropriately dilate in response to 
ischemia. Although our study measured dysfunction in the en-
dothelial cells of small digital vessels, it is likely that similar im-
pairments occur in the more distal microvasculature at sites of 
parasitized red cell sequestration. In SM, metabolic acidosis is 
proportional to disease severity and is an important risk factor 
for death ( 26 ). The acidosis is thought to result from a combi-
nation of obstructed microvascular fl ow and impaired tissue 
oxygen delivery ( 26 ) and/or utilization ( 27 ). In our study, the 
degree of endothelial dysfunction correlated with blood lactate 
and acidosis; this supports the hypothesis that endothelial dys-
function and NO defi ciency contribute to impaired microvas-
cular fl ow and functional tissue hypoxia. In sepsis, another state 
of acute  l- arginine defi ciency, impairment in microcirculatory 
fl ow is reversible after infusion of the NO-donor nitroglycerin 
( 28 ). Collectively, these observations give a rational basis for 
future functional studies of microvascular perfusion and re-
versibility with  l- arginine in severe SM. 
 Endothelial dysfunction was signifi cantly greater in SM 
compared with MSM despite comparable degrees of hypoar-
gininemia in these groups. Possible reasons for this include in-
creased endothelial NO quenching in severe disease because of 
and a decrease in organ-specifi c NO production in nearly all 
adults with SM. This near-universal endothelial dysfunction in 
 Figure 3.  Change in RH-PAT index and exhaled NO after  L -arginine 
infusion. (A) Change in RH-PAT index in MSM after infusion of 100 ml saline 
(3%; 95% CI  from  − 1 to 12) or  L -arginine (19%; 95% CI  8 – 33). p-values 
refer to paired comparisons before and after infusion. Dots and bars indi-
cate means and 95% CIs. (B) Dose-related change in RH-PAT index after 
intravenous  L -arginine infusion in the a priori – defi ned subset of patients 
with MSM who had baseline endothelial dysfunction (RH-PAT index   1.67; 
 n  14; P  0.03). Lines show RH-PAT index before and after intravenous 
 L -arginine at doses of 3, 6, and 12 g. In the 16 patients without baseline 
impairment of endothelial function (RH-PAT index   1.67), there was no 
signifi cant change in RH-PAT after  L -arginine infusion. (C) Change in exhaled 
NO concentration in MSM after infusion of 100 ml saline (18%; 95% CI  
from  − 2 to 28) or  L -arginine (55%; 95% CI  39 – 71). p-values refer to 
paired comparisons before and after infusion. Dots and bars indicate 
means and 95% CIs. 
 o
n
 N
ovem
ber 11, 2013
jem.rupress.org
D
ow
nloaded from
 
Published October 22, 2007
2700 L-ARGININE – REVERSIBLE ENDOTHELIAL DYSFUNCTION IN MALARIA | Yeo et al.
the failure to control for dietary nitrate ingestion, nitrate 
retention in renal failure, and perturbations in extracellular fl uid 
volumes ( 41, 42 ). Experiments that have controlled for these 
variables have shown reduced concentrations of NO metabo-
lites and impaired expression of NOS in circulating mono-
nuclear cells in SM ( 9 ). Although not possible to measure in 
those with coma, our real-time measurement of exhaled NO 
has provided the fi rst direct measurement of NO in malaria and 
demonstrates impaired organ-specifi c NO production in severe 
disease. We speculate that the impaired pulmonary NO pro-
duction we demonstrate in this study in SM may increase the 
risk of developing acute respiratory distress syndrome (ARDS), a 
syndrome that usually commences 1 – 6 d after starting antima-
larial treatment and is a major cause of death in SM ( 43 ) 
Pulmonary NO is reduced in patients with ARDS in other 
diseases ( 44 ), and NO production has been associated with 
improved outcomes from acute lung injury ( 45 ). In animal 
experiments, disruption of extracellular  l- arginine uptake is as-
sociated with decreased NO production and increased lung 
infl ammation ( 46 ). By increasing pulmonary NO,  l- arginine 
therapy could potentially reduce the risk of developing 
ARDS in SM. 
 Our study has several limitations. The allocation of patients 
to receive either  l- arginine or saline was not randomized. 
However, there were no diff erences in baseline characteristics 
between those receiving saline and  l- arginine, and neither of 
the primary outcome measures was subjective. We could not 
exclude concurrent infections, particularly in SM. However, 
the low frequency of secondary bacteremia in SM in adults 
( 47 ) makes it unlikely that concurrent bacterial infection could 
explain the near-universal impairment of endothelial function 
in SM. Exhaled NO may not refl ect systemic NO production 
( 48, 49 ), and we could not directly measure intracellular endo-
thelial NO concentrations. Although RH-PAT response is at 
least 50% NO dependent, we were unable to exclude other 
mechanisms for endothelial dysfunction in SM, such as con-
current defi ciency of endothelium-derived hyperpolarizing 
factor and prostacyclin ( 19 ). However, the increase in both endo-
thelial function and exhaled NO after  l- arginine infusion sug-
gests an ability to increase NO bioavailability in at least two 
cell types. Our LDH results are comparable to previous studies 
in malaria ( 50 ). We cannot exclude a contribution to plasma 
LDH levels from extraerythrocytic sources, but the relative 
contribution from parasite LDH is likely to be minor. Finally, 
we cannot exclude eff ects of other factors (e.g., a high fat diet 
[ 19 ] or diurnal variation [ 51 ]) on endothelial function, but 
the impact of these confounding factors is likely to be low in 
patients acutely ill with malaria. 
 The improvement in endothelial function after  l- argi-
nine infusion in MSM was greatest in those with baseline 
impairment of endothelial function. With endothelial dys-
function occurring in nearly all patients with SM, the po-
tential benefi t of  l- arginine infusion in SM may be greater 
than that we have demonstrated in MSM.  l- arginine infusion 
was used in patients with MSM in this study because of the 
need to collect pharmacokinetic data and to demonstrate 
a greater degree of hemolysis, greater hypoargininemia-related 
superoxide production, and/or more microvascular sequestra-
tion of parasitized red cells than in MSM. In patients with 
SCD, hemolysis leads to an increase in plasma cell – free hemo-
globin and arginase, resulting in NO scavenging and metabo-
lism of plasma  l- arginine, respectively, each of which reduces 
NO bioavailability ( 14, 17 ). In SCD, plasma LDH (from lysed 
erythrocytes) and reduced  l- arginine/ornithine ratio (refl ect-
ing plasma arginase activity) are associated with up-regulation 
of endothelial adhesion receptors,  l- arginine – reversible endo-
thelial dysfunction, and early mortality ( 15 – 18 ). Our study 
suggests that similar mechanisms may be operating in SM. 
LDH was highest in SM and was associated with endothelial 
dysfunction, increased expression of plasma endothelial adhe-
sion molecules, and increased mortality. 
 Greater endothelial dysfunction in SM may also relate to 
the dependence of endothelial NO production on the activity 
of the cationic amino acid transporters responsible for cellular 
uptake of extracellular  l- arginine ( 29 ). As in African children 
with cerebral malaria ( 10 ), the mean plasma  l- arginine con-
centration in adults with SM was below the half-saturating 
concentration (Km) of the cationic amino acid transporters 
(100 – 150   mol/liter), making it likely that hypoargininemia 
limits  l- arginine transport into cells and NO production in 
severe disease in both adults and children. With low  l- argi-
nine levels, NOS generates superoxide rather than NO, re-
sulting in oxidant-mediated cellular damage ( 30, 31 ), with 
NO quenching by superoxide further reducing NO bioavail-
ability. Because patients with SM may have increased expres-
sion of NOS2 in endothelial cells ( 32 ), increased endothelial 
superoxide generation and local quenching of NO may con-
tribute to the greater endothelial dysfunction found in SM. 
In addition, the greater dysfunction in SM may result from 
parasite-mediated eff ects on endothelial cells associated with a 
larger biomass of parasitized red cells adherent to the endothe-
lium. Sequestration of parasitized red cells may be both a cause 
and an eff ect of endothelial dysfunction. 
 Possible causes of hypoargininaemia in SM include de-
creased  l- arginine synthesis and increased catabolism caused 
by the increased activity of plasma arginase ( 33 ) and/or cyto-
kine-inducible arginase in endothelial cells or immune cells 
( 34, 35 ), processes that may also occur in other infl ammatory 
conditions. As well as impairing endothelial function, hypoar-
gininemia and NO defi ciency may contribute to pathology in 
SM through other mechanisms. NO inhibits platelet activa-
tion ( 36 ), and defi ciency may therefore exacerbate platelet-
mediated processes linked to the microvascular pathology of 
SM, including endothelial cell activation ( 37 ) and apoptosis 
and platelet-mediated clumping ( 38 ). Because NO is also a 
determinant of red cell deformability ( 39 ), defi ciency of NO 
may exacerbate the impaired red cell deformability found in 
SM ( 40 ), further compromising microvascular perfusion. 
 The extremely short half-life of NO has made measure-
ment of NO production technically challenging in malaria, 
with most studies measuring concentrations of NO metabolites 
in body fl uids. Results have been diffi  cult to interpret because of 
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 Ethical approval was obtained from the Health Research Ethics Com-
mittees of the National Institute of Health Research and Development, 
(Indonesia) and the Menzies School of Health Research (Australia). Written 
informed consent was obtained from patients or attending relatives in Indo-
nesian or a local language, when necessary. 
 Stage 1 clinical observations.  At enrollment, all patients underwent a 
standardized medical history, physical examination, venous blood collection, 
and measurement of endothelial function and exhaled NO. Blood pressure 
was measured with an automated sphygmomanometer and axillary tempera-
ture with a digital thermometer. 
 Laboratory methods.  Hemoglobin and white blood cell counts were mea-
sured by a counter (T890; Beckman Coulter), and routine biochemistry, 
acid-base parameters, and lactate were measured using a bedside biochemical 
analyzer (i-STAT-1; i-STAT Corp.). Parasite counts were determined by 
Giemsa-stained thick and thin fi elds and were cross-checked by an experi-
enced microscopist. Plasma was separated within 30 min of collection by 
centrifugation and stored at  − 70 ° C. Amino acids were extracted from 50   l 
of plasma after the addition of 50   l of internal standard (norleucine) and 200   l 
of cold ethanol. Deproteinized plasma was derivitized with AccQFluor re-
agent (Waters), and amino acids were measured by HPLC (Shimadzu) using 
a method modifi ed from van Wandelen and Cohen ( 55 ). Plasma concentra-
tions of the endothelial activation markers soluble ICAM-1 and E-selectin 
were assayed by ELISA (R & D Systems). To quantitate total parasite biomass, 
plasma HRP2 was measured by ELISA, as previously described ( 56 ). Purifi ed 
HRP2 was provided by D. Sullivan (Johns Hopkins University, Baltimore, 
MD). Plasma haptoglobin and LDH were measure by ELISA and a calori-
metric assay, respectively (Roche Diagnostics). Plasma arginase activity was 
measured using a radiometric assay, as previously described, and reported as 
micromole/milliliter/hour ( 16 ). 
 Endothelial function.  RH-PAT (Itamar) is a recently validated noninvasive 
method of assessing endothelial function. RH-PAT correlates with the more 
labor-intensive fl ow-mediated dilatation method ( 57 ) and endothelial func-
tion in other vascular beds ( 57 ). At least 50% of RH is dependent on endo-
thelial NO production ( 24 ). Finger probes measure digital volume changes 
detected by a pressure transducer. PAT was measured before and after a 5-min 
ischemic stress, generating an RH-PAT index, normalized to the control 
arm ( 57 ). All studies were performed in a quiet air-conditioned room at 25 ° C 
after a 20-min equilibration time. In 10 patients with SM, tests were per-
formed in a high dependency unit at similar temperatures. To internally vali-
date endothelial function measurements, RH-PAT indices were repeated 
0.5 – 0.75 h after initial measurements in 37 HC. The reproducibility coeffi  -
cient was 0.59 ( 58 ), comparable with previous results ( 59 ) and those obtained 
with the fl ow-mediated dilatation method ( 51 ). 
 Exhaled NO.  Fractional concentration of exhaled NO in ppb was mea-
sured using American Thoracic Society guidelines with an NO analyzer 
(NiOX; Aerocrine AB) at a fl ow rate of 250 ml/sec ( 60 ). 
 Stage 2: eff ect of  L -arginine infusion on endothelial function.  A single 
ascending dose study of  l- arginine infusion was undertaken in 30 additional 
subjects with MSM ( Fig. 1 ). This stage was designed to assess safety, pharma-
cokinetics, and proof of mechanism and concept that  l- arginine infusion 
increases NO production and improves endothelial function. 
 Stage 2 patients.  30 additional patients with MSM were enrolled for 
 l- arginine infusion, with the same inclusion and exclusion criteria as in stage 
1 and the additional exclusion criterion of known allergy to  l- arginine. 
Based on the known variability of endothelial function ( 59 ), this sample size 
gave an 80% power to detect a 10% increase in RH-PAT index after  l -arginine 
infusion. A control group comprised the 48 patients with MSM from stage 1 
( Fig. 1 ). These patients underwent identical assessments before and after a 
30-min infusion of 100 ml of normal saline. 
safety and proof of concept before proceeding to studies in 
severe disease. 
 In conclusion, SM is characterized by hypoargininemia, 
hemolysis, decreased pulmonary NO, and impairment of 
endothelial function, with each potentially contributing to its 
pathogenesis. Given its central role in malaria pathophysiol-
ogy, the endothelium may be an important therapeutic target 
for adjunctive treatment. Short-term parenteral  l- arginine 
therapy is safe in MSM and increases pulmonary NO pro-
duction. Its effi  cacy in improving endothelial function sug-
gests that hypoargininemia and decreased NO bioavailability 
contribute to endothelial dysfunction. Our work provides 
fi rm proof of concept to warrant clinical trials of adjunctive 
agents such as  l- arginine to improve endothelial NO bio-
availability in SM. 
 MATERIALS AND METHODS 
 Study design 
 Stage 1: relationship between endothelial function and disease 
severity.  An initial prospective cross-sectional observational study was con-
ducted to compare endothelial function, plasma  l- arginine concentrations, 
exhaled NO, and biochemical markers among patients with MSM and SM 
and healthy individuals ( Fig. 1 ). Patients were enrolled between February 
2005 and April 2006. 
 Stage 1 patients.  The study was conducted at Mitra Masyarakat Hospital in 
Timika, Papua, Indonesia, a region with unstable transmission of both  Plas-
modium falciparum and  P. vivax ( 52 ). Three groups of adults  	 18 yr old were 
enrolled from the emergency department or outpatient clinic and diff erenti-
ated as follows: (a) MSM, defi ned as fever or history of fever in the past 48 h, 
with   1,000 asexual  P. falciparum parasites per microliter (a parasitemia 
threshold predicting clinical disease in Papua) ( 53 ), no other etiology identi-
fi ed, and requiring inpatient parenteral therapy because of the inability to 
tolerate oral therapy ( 54 ) but exhibiting no World Health Organization 
(WHO) warning signs or criteria for SM ( 22 ); (b) SM, defi ned as the pres-
ence of  P. falciparum parasitaemia and  	 1 modifi ed WHO criteria of severity 
( 22, 43 ), a Glasgow coma score   11, renal failure (creatinine   265   mol/
liter after rehydration or urine output of   400 ml per 24 h), hyperbilirubi-
naemia (total bilirubin   50   mol/liter) with either renal impairment (creat-
inine   130   mol/liter) or parasitaemia (  100,000 parasites per microliter), 
blackwater fever, hypoglycemia (whole blood glucose   2.2 mmol/liter), 
respiratory distress (respiratory rate   32 breaths/min), acidosis (venous bi-
carbonate   15 mmol/liter), shock (systolic blood pressure   80 mmHg after 
fl uid resuscitation with cold peripheries), and/or hyperparasitaemia (  10% 
parasitized red cells); and (c) HC, defi ned as unrelated hospital visitors, sub-
jectively well with no history of fever in the preceding 48 h, no parasitaemia, no 
concurrent illness or medication, and not having smoked within the preceding 
12 h. Exclusion criteria included the following: pregnant or breastfeeding 
women; patients treated with parenteral antimalarials for   18 h; mixed 
 P. falciparum / P. vivax infections; diabetes; known cardiac, renal, or hepatic 
disease; concurrent infection; concurrent medication; hemoglobin   60g/liter; 
and among MSM, those with systolic blood pressure   100 mmHg, a base-
line venous bicarbonate level   20 mmol/liter, potassium  	 4.2 mmol/liter, 
glucose   4 mmol/liter, or chloride   106 mmol/liter. 20 patients with SM 
were initially randomized to either intravenous quinine or artesunate as part 
of a multicenter clinical trial ( 1 ) . Based on the results of the study and an en-
suing national policy change, all patients subsequently received intravenous 
artesunate. Individuals with MSM were treated with intravenous quinine in 
accordance with national guidelines. Both groups also received doxycycline 
or clindamycin. Supportive care, including antibiotics and fl uid administra-
tion, was provided at the discretion of the treating physicians, who were 
independent of the study. 
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 L- arginine infusion.  In a sequential single ascending dose design,  l- arginine 
hydrochloride (Pharmalab) was diluted in 100 ml of normal saline (or suffi  cient 
to provide a concentration  
 10% wt/vol) and administered intravenously by 
an infusion pump over 30 min at doses of 3 ( n  10), 6 ( n  10), and 12 g 
( n  10). Patients received intravenous quinine and clinical care as in stage 1. 
 Stage 2 clinical, physiologic, and biochemical observations.  All pa-
tients underwent the same baseline measurements as in stage 1. To assess 
safety, patients were monitored with serial assessments of symptoms, vital 
signs, and biochemistry (blood potassium, glucose, bicarbonate, pH, chloride, 
and phosphate) until discharge. Exhaled NO and plasma  l- arginine were 
measured immediately before and after infusion. RH-PAT measurement was 
completed within 10 min before infusion and within 20 min after infusion. 
 Stage 2 outcome measures.  The primary outcome measures were the 
changes in RH-PAT index and exhaled NO after  l -arginine infusion. 
Changes in RH-PAT index and exhaled NO in stage 2 MSM patients given 
 l- arginine were compared with changes seen in patients with MSM in stage 1 
who had been given an identical volume of normal saline. Primary safety 
outcomes were changes in hemodynamic measures and electrolytes. 
 Secondary outcome measures were the change in RH-PAT index in 
the a priori subgroup of patients with baseline impairment of endothelial 
function (predefi ned as an index of   1.67) ( 23 ) and evidence for dose de-
pendency of the change in RH-PAT index among all patients and among 
those with baseline impairment of endothelial function. 
 Statistical methods 
 For cross-sectional analyses, continuous variables with a normal distribution 
were compared among groups by analysis of variance (ANOVA) or the 
Student ’ s  t test. The Mann-Whitney U test or the Kruskal-Wallis test was 
used when data were not normally distributed. Pearson ’ s method was used 
to estimate correlation between normally distributed continuous variables. 
Comparison of paired proportions and paired continuous variables used 
McNemar ’ s   2 test and the paired  t test, respectively. All analyses were per-
formed with Stata software (version 8.2; Statacorp.). A two-sided value of 
P   0.05 was considered signifi cant. 
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